Organization
Alaunos Therapeutics
3 clinical trials
1 abstract
Clinical trial
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Using the Sleeping Beauty System to Express T Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid TumorsStatus: Recruiting, Estimated PCD: 2039-04-01
Clinical trial
Phase I/II Study of Autologous T Cells Engineered Using the Sleeping Beauty System to Express T-Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab-rwlc (Libtayo®) in Subjects With Recurrent or Progressive GlioblastomaStatus: Completed, Estimated PCD: 2021-08-05
Abstract
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Alaunos Therapeutics,